

PEER-REVIEW REPORT

Name of journal: World Journal of	of Gastroenterology
-----------------------------------	---------------------

Manuscript NO: 78409

Title: Combination Strategies for Pharmacologic Treatment of Non-Alcoholic

Steatohepatitis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06245556

Position: Peer Reviewer

Academic degree: DPhil

Professional title: Doctor

Reviewer's Country/Territory: Australia
Author's Country/Territory: United States

Manuscript submission date: 2022-06-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-25 10:55

Reviewer performed review: 2022-06-26 22:10

Review time: 1 Day and 11 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this minireview the authors discuss the role of combination therapeutics in treating nonalcoholic steatohepatitis. Overall the review is informative and well-written but would benefit from a number of improvements. Introduction: - NASH definition, include other important factors such excluding alcohol as excessive consumption >20g/day women or >30g/day men, and excluding other causes of liver disease. -"Liver specific targets aimed at decreasing histologic inflammation or fibrosis such as farnesoid X receptor (FXR) agonists or peroxisome proliferator-activated receptor (PPAR) agonists." This is not a complete sentence and needs to be rephrased. -Where is the figure mentioned in-text, figure 1, table 1 etc.? These are not included in the manuscript. -"As such, it was no surprise that a previously terminated clinical trial attempted to combine the effects of pioglitazone and roflumilast, a potent anti-inflammatory drug used in chronic pulmonary disease trials. " Please could the authors clarify what they mean by this statement?



PEER-REVIEW REPORT

Name of journal: V	Norld J	ournal of	Gastroenterol	ogy
----------------------	---------	-----------	---------------	-----

Manuscript NO: 78409

Title: Combination Strategies for Pharmacologic Treatment of Non-Alcoholic

Steatohepatitis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03538879 Position: Editorial Board Academic degree: MD, PhD

Professional title: Chief Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2022-06-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-06-27 02:53

Reviewer performed review: 2022-06-28 05:51

Review time: 1 Day and 2 Hours

Scientific quality	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish	
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection	
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection	
Re-review	[Y]Yes []No	



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this minireview, the authors discussed the current drug development pipeline of NASH, target pathways associated with NASH pathogenesis, and evaluated the multimodal combination strategy. Since NASH is a complex disease, the combination strategy might be superior to mono-therapeutic options, and represent new direction for NASH treatment.



RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 78409

Title: Combination Strategies for Pharmacologic Treatment of Non-Alcoholic

Steatohepatitis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06245556

Position: Peer Reviewer

Academic degree: DPhil

Professional title: Doctor

Reviewer's Country/Territory: Australia

Author's Country/Territory: United States

Manuscript submission date: 2022-06-24

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2022-07-28 11:19

Reviewer performed review: 2022-07-28 11:25

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors have made appropriate changes to the manuscript.